IRIS and AEYE Health Announce Partnership to Provide AI Screening to Market

Intelligent Retinal Imaging Systems (IRIS) announced a partnership with AEYE Health, an artificial intelligence company for retinal imaging and diagnostics. Under the agreement, IRIS will license AEYE Diagnostic Screening (AEYE-DS) from AEYE Health, which is an FDA-cleared AI technology that seamlessly integrates with the IRIS Solution.

Financial terms of the deal were not disclosed. 

This partnership allows IRIS customers to use AEYE-DS for the autonomous detection of diabetic retinopathy alongside the IRIS solution and receive an instantaneous result using only one image per eye. In an FDA clinical study (clearance K221183) for the detection of more-than-mild diabetic retinopathy, the AEYE-DS was found to have 93% sensitivity and over 91.4% specificity using one image per eye captured by the Topcon NW400 fundus camera.

"We are pleased to partner with AEYE Health. Now a number of IRIS customers can utilize the best-in-class artificial intelligence tool for the early detection of diabetic retinopathy," Steve Martin, CEO of IRIS, said in a news release. "Their unique single-image-per-eye screening requires less work and produces superior accuracy as demonstrated in their clinical trial. Furthermore, we are excited about the additional camera models that will be available for use with AEYE-DS in the future."

"This partnership with IRIS allows AEYE Health to reach a higher level of adoption due to IRIS's impressive footprint in over 600 clinics, pharmacies, and labs," said Zack Dvey-Aharon, PhD, Co-Founder & CEO of AEYE Health. "In the future, our hope is to provide a camera option that IRIS customers can leverage in the 150,000 annual DR screenings that are performed during in-home visits."